Medical treatment of Cushing's disease: Somatostatin analogues and pasireotide

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 120-124

  Pedroncelli, Alberto M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cushing's disease; Pasireotide; Somatostatin analogue

Indexed keywords

CABERGOLINE; CORTICOTROPIN; HYDROCORTISONE; KETOCONAZOLE; PASIREOTIDE;

ABDOMINAL PAIN; ACTH SECRETING ADENOMA; AREA UNDER THE CURVE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CUSHING DISEASE; DIARRHEA; DRUG INDICATION; ECTOPIC CORTICOTROPIN PRODUCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOPHYSECTOMY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

HUMANS; PITUITARY ACTH HYPERSECRETION; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 77956551606     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314352     Document Type: Conference Paper

References (19)

1. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buch-felder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M: Treatment of ACTH-depen-dent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 20 08; 93: 2454-2462.
2. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newe l l-P r ic e J, Niem a n LK, S on i no N, Va nce ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88:5593-5602. (Pubitemid 38033020)
3. Findling JW, Raff H: Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 2006; 91: 374 6-3753.
4. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, Van Aken MO, Voormolen JH, Romijn JA: Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007; 92:976-981.
5. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet 2006; 367:1605-1617.
6. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G: Failure of somatostatin and oc-treotide to acutely affect the hypothalamic-pituitary- adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990; 13: 257-261.
7. Lamberts SW, Uitterlinden P, Klijn JM: The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989; 120:760-766.
8. Invitti C, De Martin M, Brunani A, Piolini M, Cavagnini F: Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin En-docrinol (Oxf) 1990; 32:275-281.
9. Comi RJ: Octreotide: a 15-year update. En-docrinologist 2006; 16:86-90.
10. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatosta-tin peptidomimetic with broad somatotro-pin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-716.
11. Hofland LJ, Lamberts SW: Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 2004; 32:235-252.
12. Hofland LJ: Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell En-docrinol 2008; 286: 19 9-205.
13. Schmid HA, Tran LL, Wang Y, Glusman JE: Preclinical and clinical experience with the novel multi-ligand somatostatin analog, SOM230 (abstract). Endocr Pract 2005; 11: 836.
14. Hofland LJ, Van Der Hoek J, Feelders R, Van Aken MO, Van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, De Herder WW, Beckers A, Lamberts SWJ: The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via so-matostatin receptor type 5. Eur J Endocrinol 2005; 152: 645-654.
15. Van Der Hoek J, Waaijers M, Van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ: Distinct functional properties of native soma-tostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. Am J Physiol Endocrinol Metab 2005; 289:E278-E287.
16. Boscaro M, Ludlam WH, Atkinson B, Glus-man JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J: Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand so-matostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 20 09; 94: 11 5-1 2 2.
17. Pivonello R, De Martino MC, Cappabianca P, De L M, Fa g g ia no A, L ombard i G, Hof la nd LJ, Lamberts SW, Colao A: The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2008; 94: 223-230.
18. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura E Silva, Agra R, Pontes L, Montenegro L, Albuquerque JL, Canadas V: Effectiveness of cabergoline in monother-apy and combined with ketoconazole in the management of Cushing's disease. Pituitary 2010; 13: 123-129.
19. Feelders R, De Bruin C, Pereira AM, Netea-Maier RT, Hermus A, Zelissen PM, De Jong FH, Van Der Lely AJ, De Herder WW, Hof land LJ, Lamberts SW: Stepwise medical treatment of Cushing's disease in a prospective, open label, multi-center trial: pasireotide mono-or combination therapy with a dopa-mine agonist and low-dose ketoconazole induces biochemical remission in 13 out of 15 patients (abstract S21-S25); in 91st Annu Meet Endocrine Soc, Washington, 2009.